| 1. |
|
|
| 2. |
- Eilers, Hinnerk, et al.
(författare)
-
Effect of GT-Peptide 10 and Triethyl Citrate on P. acnes Biofilm Formation, Viability, and Dispersion
- 2016
-
Ingår i: Journal of drugs in dermatology. - 1545-9616. ; 15:6, s. 778-781
-
Tidskriftsartikel (refereegranskat)abstract
- Background: P. acnes biofilms are emerging topics in acne vulgaris pathogenesis and may be responsible for antibiotic tolerance. Objective: To investigate the efficacy of GT peptide 10 either alone or in combination with triethyl citrate (TEC) in in vitro model of P acnes biofilm. Methods: Six-day-old P acnes biofilms were treated with various concentrations of these substances and biofilm dispersion and cell viability were monitored. Results: A 24-hour exposure of preformed biofilms to a combination of GT peptide 10/TEC led to killing of up to 92% of bacterial cells inside the biofilm. Neither the single substance nor the combination of both substances affected the biofilm integrity or resulted in biofilm dispersal. Conclusions: A combination of GT peptide 10/TEC shows antibacterial effects in in vitro model of P. acnes biofilm.
|
|
| 3. |
|
|
| 4. |
- Lindberg, Ingrid, et al.
(författare)
-
Persistence with biologic treatments in psoriasis : A structured literature review of studies using administrative database and clinical registry data
- 2022
-
Ingår i: Journal of Drugs in Dermatology. - : Journal of Drugs in Dermatology. - 1545-9616. ; 21:8, s. 881-889
-
Forskningsöversikt (refereegranskat)abstract
- Background: Psoriasis is a chronic, autoimmune-mediated inflammatory disorder. Drug persistence is a composite measure of effectiveness, safety, and treatment satisfaction, often estimated using data from administrative databases and clinical registries. Persistence rates calculated from these two data sources appear to be systematically different.Objective: Review and compare persistence rates of psoriasis-indicated biologics reported in registry and database studies.Methods: A structured literature search of studies published during 2009-2019 was performed in PubMed and American Academy of Dermatology records to identify research describing persistence with biologic treatments in psoriasis patients. English language retrospective or prospective persistence studies based on database or registry data, and reporting on at least two psoriasis-indicated biologics, of which at least one was ustekinumab, secukinumab, ixekizumab or guselkumab, were included. Single-arm studies, randomized control trials, systematic literature reviews, and studies presenting stratified results only were excluded.Results: A total of 37 studies (22 registry- and 15 database-derived) comprising 76,000 patients were included. On average, drug persistence collected from registry studies was 18% higher than database studies.Conclusion: The findings of this study may be used by practitioners to make meaningful comparisons between persistence data derived from registries and databases, and thereby improve clinical decision making.
|
|
| 5. |
|
|
| 6. |
- Ohison, Johan, et al.
(författare)
-
Observational Study of Clindamycin Phosphate and Tretinoin Gel for the Treatment of Acne
- 2019
-
Ingår i: JOURNAL OF DRUGS IN DERMATOLOGY. - : JOURNAL OF DRUGS IN DERMATOLOGY. - 1545-9616. ; 18:4, s. 328-334
-
Tidskriftsartikel (refereegranskat)abstract
- Introduction: Acne vulgaris can cause pain/discomfort and have a negative impact on quality of life (QOL). Clin-RA is an acne treatment consisting of clindamycin phosphate 1.2% and tretinoin 0.025%, which has been proven effective and well tolerated in clinical studies. This prospective, non-interventional study aimed to capture data on previous treatment, acne severity, and QOL in patients with acne treated with Clin-RA and assess the efficacy and tolerability of Clin-RA in routine clinical practice.Methods: The study was performed at 18 centers in Sweden and enrolled patients aged >= 15 years with acne, who were prescribed Clin-RA for the first time. The observation period was similar to 12 weeks. The primary objective was to assess the patient's perception of their facial acne severity before and during Clin-RA treatment using a visual analog scale (VAS; 100 mm scale). Secondary objectives included QOL evaluation before and after treatment, using the Dermatology Life Quality Index (DLQI) questionnaire.Results: 84 patients were enrolled and eligible for analyses (79.8% female; mean age 22.6 years). Patient-assessed VAS scores for acne severity decreased continuously during the study, indicating improvement: the median percentage reduction from baseline for VAS score was 17.6% at week 4 and 63.8% at week 12, with changes from baseline being statistically significant (P=0.0004 at week 4; P<0.0001 at weeks 8 and 12). Overall, QOL improved after Clin-RA treatment, reflected by a decrease in the mean (standard deviation) DLQI sum score from 8.8 (5.8) on day 0 to 4.9 (4.2) at week 12. Seventy percent of patients were satisfied/very satisfied with treatment. Clin-RA was well tolerated, with no serious adverse drug reactions reported.Conclusions: Treatment with Clin-RA resulted in continuous improvement of facial acne over the course of 12 weeks, along with improved QOL and a tolerable safety profile, supporting the use of Clin-RA in clinical practice.
|
|
